Search

Rhythm Pharmaceuticals Inc

Закрыт

СекторЗдравоохранение

104.41 -0.12

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

103.67

Макс.

106.84

Ключевые показатели

By Trading Economics

Доход

-49M

-105M

Продажи

11M

71M

Прибыль на акцию

-0.73

Рентабельность продаж

-147.27

Сотрудники

414

EBITDA

6.2M

-44M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+31.62% upside

Дивиденды

By Acuity

Следующий отчет о доходах

3 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

623M

7.7B

Предыдущая цена открытия

104.53

Предыдущая цена закрытия

104.41

Новостные настроения

By Acuity

36%

64%

119 / 340 Рейтинг в Healthcare

Rhythm Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

31 авг. 2026 г., 23:46 UTC

Rhythm Pharmaceuticals Inc shares rose in after-market trading, reflecting a gradual increase from earlier lows, though still below the 20-day moving average.

28 авг. 2026 г., 20:02 UTC

News

Rhythm Pharmaceuticals Inc shares are lower as Deutsche Bank initiates coverage with a Hold rating and a price target of $120.

26 авг. 2026 г., 20:08 UTC

News

Rhythm Pharmaceuticals is trading lower, influenced by declines in the Biotechnology sector and a broader market downturn since Tuesday's close.

25 авг. 2026 г., 21:02 UTC

Rhythm Pharmaceuticals Inc shares are lower in after-market hours. No specific news was identified to explain the decline, contrasting recent upward trends.

21 авг. 2026 г., 19:36 UTC

Rhythm Pharmaceuticals Inc shares are higher during Friday's session, reflecting positive market response. The stock reached a session high earlier before pulling back.

20 авг. 2026 г., 20:02 UTC

Correlated Moves

Rhythm Pharmaceuticals is lower today, influenced by a significant decline in the Biotechnology sector and high trading volume. The stock has dropped sharply since Wednesday.

13 авг. 2026 г., 19:51 UTC

Rhythm Pharmaceuticals is advancing amid broader market gains, supported by strong technology sector performance and high trading volume, despite no specific company news.

12 авг. 2026 г., 19:46 UTC

Event

Rhythm Pharmaceuticals received expanded marketing authorization for IMCIVREE in the UK. Shares are trading higher since Tuesday's close, near the upper end of their one-month range.

11 авг. 2026 г., 19:36 UTC

Social Media
News
Event

Rhythm Pharmaceuticals received expanded UK approval for IMCIVREE to treat obesity, yet shares are declining amid broader market sentiment concerns.

10 авг. 2026 г., 19:31 UTC

Rhythm Pharmaceuticals Inc shares are lower today, retracing gains after an early drop. The stock is experiencing unusually high trading volume.

7 авг. 2026 г., 20:06 UTC

News

RYTM higher after JPMorgan raised price target to $146.00.

6 авг. 2026 г., 21:05 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reaching a high and remaining above the 20-day moving average. No specific news was identified.

5 авг. 2026 г., 20:02 UTC

Event
News

Rhythm Pharmaceuticals shares rise as Citigroup, RBC, and Citizens raise price targets to $143, $155, and $160, respectively, reflecting growing confidence in the company.

4 авг. 2026 г., 20:13 UTC

News

Rhythm Pharmaceuticals shares are trading higher in after-market hours following CEO and CFO participation in upcoming investor conferences, enhancing visibility among stakeholders.

3 авг. 2026 г., 19:51 UTC

Rhythm Pharmaceuticals Inc shares are higher today amid unusually high trading volume, continuing the upward trend since Friday's close. No specific news was identified.

31 июл. 2026 г., 22:56 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, despite earlier fluctuations and no specific news identified to explain the movement.

30 июл. 2026 г., 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, continuing a downward trend since Wednesday. No specific news has been identified to explain the decline.

29 июл. 2026 г., 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, influenced by rising oil prices amid escalating Middle East tensions, though no specific company news was identified.

28 июл. 2026 г., 19:11 UTC

Rhythm Pharmaceuticals Inc. shares are higher today, supported by strong trading volume and positive momentum in the biotechnology sector. No specific news was identified.

27 июл. 2026 г., 19:33 UTC

News

RYTM trades higher after JPMorgan's Overweight rating and $145 target.

24 июл. 2026 г., 21:01 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reflecting a positive shift since Friday's close despite broader market challenges.

21 июл. 2026 г., 14:36 UTC

News

Rhythm Pharmaceuticals will report second-quarter 2026 results on August 4, contributing to higher shares amid positive market sentiment and gains in the Nasdaq 100 Index.

20 июл. 2026 г., 20:51 UTC

Rhythm Pharmaceuticals Inc is lower in after-market trading, down significantly from Monday's close and below its 20-day moving average. No specific news was identified.

Сравнение c конкурентами

Изменение цены

Rhythm Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

31.62% рост

Прогноз на 12 месяцев

Средняя 141.06 USD  31.62%

Максимум 160 USD

Минимум 105 USD

Основано на мнении 16 аналитиков Wall Street, спрогнозировавших целевые цены для Rhythm Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

16 ratings

15

Покупка

1

Удержание

0

Продажа

Настроения

By Acuity

119 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat